Preclinical data indicate that targeting CTLA-4 can disrupt this interaction, restore T-cell activation, and enhance anti-tumor immunity, supporting the exploration of CTLA-4 inhibitors as a potential therapeutic option, particularly in PD-1-refractory cHL [8]. This evidence concerns the gene CTLA4 and neoplasm.